Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

Annovis (NYSE: ANVS) launched a proposed underwritten public offering of common stock and accompanying warrants, which must be purchased together.

Rhea-AI Summary

Annovis (NYSE: ANVS) launched a proposed underwritten public offering of common stock and accompanying warrants, which must be purchased together. All securities are offered by the company, with Canaccord Genuity as sole bookrunner.

Net proceeds are expected to fund Phase 3 development of buntanetap for Alzheimer’s disease, plus working capital and general corporate purposes. The offering’s completion, size and terms remain subject to market and other conditions.

Positive

• Equity and warrant offering to fund Phase 3 buntanetap trial
• Proceeds also earmarked for working capital and corporate purposes
• Use of effective Form S-3 shelf may streamline capital raising

Negative

• Common stock and warrant issuance implies potential shareholder dilution
• Offering completion, size and terms remain uncertain and market dependent

Argus May 20 session

+5.15% close to close Open Argus

Details

News Market Reaction – ANVS

On May 20, the first trading day after this news, ANVS closed 5.15% above the previous close.

Data tracked by StockTitan Argus for the May 20 session.

Key Figures

Clinical stage: Phase 3 Shelf registration form: Form S-3 No. 333-276814 Shelf filing date: February 1, 2024 +1 more

Clinical stage

Phase 3

Development stage of buntanetap program cited in offering release

Shelf registration form

Form S-3 No. 333-276814

Registration statement referenced for this public offering

Shelf filing date

February 1, 2024

Date Form S-3 registration statement was filed with SEC

Shelf effective date

February 12, 2024

Date Form S-3 registration statement was declared effective

Previous Offering Reports

5 past events · Latest: Apr 09

Same Type 5 events

1. Apr 09

   Underwritten offering

   24h Move

   -29.6%

   Priced $10M underwritten stock and warrant offering at $1.90 per unit.

2. Oct 27

   Registered direct sale

   24h Move

   +4.9%

   Announced $3.4M registered direct offering at-the-market under NYSE rules.

3. Oct 15

   Offering closing

   24h Move

   +12.2%

   Closed $6.0M registered direct stock (or pre-funded warrant) offering.

4. Oct 10

   Registered direct deal

   24h Move

   -22.7%

   Entered agreements for $6M registered direct stock sale at $1.50 per share.

5. Feb 04

   Public equity raise

   24h Move

   +0.0%

   Closed $21M public offering of shares and warrants to fund Phase 3 buntanetap.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, warrants, phase 3, shelf registration statement, +4 more

8 terms

underwritten public offering financial

"today announced a proposed underwritten public offering in which it intends"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

warrants financial

"shares of its common stock and (ii) accompanying warrants to purchase shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

phase 3 medical

"a Phase 3 clinical-stage biotechnology company developing the investigational"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

shelf registration statement regulatory

"offered by Annovis pursuant to an effective shelf registration statement"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3 (No. 333-276814) previously filed"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus describing"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

bookrunner financial

"Canaccord Genuity is acting as the sole bookrunner in the offering."

A bookrunner is the lead bank or financial firm that organizes and manages a new securities offering, acting like a project manager who sets the price range, collects investor demand, and decides how shares are allocated. For investors, the bookrunner’s choices and reputation influence the final price, how many shares each buyer receives, and the overall chance the deal succeeds — similar to how a trusted referee shapes a fair and well-run auction.

common stock financial

"offer and sell (i) shares of its common stock and (ii) accompanying warrants"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares of common stock. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering. All of the shares of common stock and the accompanying warrants will be offered by Annovis. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Canaccord Genuity is acting as the sole bookrunner in the offering.

Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in a Phase 3 study for Alzheimer’s disease (AD), and for working capital and general corporate purposes.

The shares and the accompanying warrants are being offered by Annovis pursuant to an effective shelf registration statement on Form S-3 (No. 333-276814) previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, 30th Floor, Boston, Massachusetts 02109, or by email at prospectus@cgf.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Forward-Looking Statements

This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the intended use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:

Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:

Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Annovis (ANVS) announce on May 19, 2026 about a stock offering?

Annovis announced a proposed underwritten public offering of common stock and accompanying warrants. According to Annovis, all offered shares and warrants will be sold by the company, with Canaccord Genuity acting as sole bookrunner, subject to market and other conditions.

How will Annovis use the proceeds from its proposed ANVS stock and warrant offering?

Annovis plans to use net proceeds to continue clinical development of buntanetap in a Phase 3 Alzheimer’s study. According to Annovis, additional proceeds will support working capital needs and general corporate purposes, enhancing funding for ongoing operations and research activities.

Are the terms and size of the Annovis (ANVS) public offering finalized?

No, the size and terms of the Annovis offering have not been finalized. According to Annovis, the proposed transaction remains subject to market and other conditions, and there is no assurance regarding completion, timing, or final deal structure for investors.

What securities is Annovis (ANVS) offering in its May 2026 transaction?

Annovis intends to offer common stock together with accompanying warrants to purchase common shares. According to Annovis, the stock and warrants will be issued separately but can only be purchased together as a unit within the proposed underwritten public offering structure.

Under which SEC registration is the Annovis (ANVS) offering being made?

The Annovis offering is being made under an effective shelf registration statement on Form S-3, file number 333-276814. According to Annovis, this registration was filed February 1, 2024 and declared effective by the SEC on February 12, 2024.

How can investors access the Annovis (ANVS) preliminary prospectus for the offering?

Investors can request the preliminary prospectus from Canaccord Genuity’s Syndication Department or by email. According to Annovis, electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC’s website at www.sec.gov.